Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 12,519

Document Document Title
WO/2013/050497A1
The present invention relates to a process of preparation of L-iduronic acid and derivatives comprising a decarboxylation/intramolecular cyclisation tandem reaction. The present invention also relates to the intermediates of the process,...  
WO/2013/044928A1
The invention relates to a method for making precursors of HMO core structures comprising a step of reacting an N-acetyllactosamine or lacto-N-biose derivative donor with a lactose or N-acetyllactosamine derivative acceptor, wherein the ...  
WO/2013/048227A1
The present invention provides a hapten derivative and conjugate of a natural high intensity sweetener containing hydroxyl groups. The conjugate can be used to produce antibodies specific against the natural high intensity sweetener. The...  
WO/2013/041732A1
The present invention relates to the total chemical synthesis of the monosaccharide 35# (R' = H), the disaccharide 36# (R' ≠ H; R'' = H), the trisaccharide 37# (R' ≠ H; R'' ≠ H; R''' = H) and the tetrasaccharide 1#(R' ≠ H; R'' ...  
WO/2013/041182A1
The patent application relates to a method for producing crystalline idarubicin hydrochloride, comprising the steps of (i) preparing a mixture that contains (a) idarubicin hydrochloride, (b) at least one alcohol selected from the group c...  
WO/2013/042581A1
Provided are: a novel sialo-sugar chain; a process for producing said sialo-sugar chain; and production equipment for said sialo -sugar chain. The novel sialo-sugar chain can be easily and efficiently mass-produced by reacting a sugar wh...  
WO/2013/038430A1
Disclosed herein is 10-α/β-D-Arabinofuranosylundecenes of general Formula (II) or pharmaceutically acceptable salts thereof as anti-mycobacterial agents in vitro; (II) wherein R, R1 and R" are as defined herein in the specification. Th...  
WO/2013/037566A1
The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory ...  
WO/2013/034119A1
The invention relates to phenoxy derivatives having glycosidically bound sugar residues, to pharmaceutical compositions containing such compounds, to the uses of such compounds and compositions, and to methods for producing such compound...  
WO/2013/022985A2
The present invention relates to compounds involved in nematode signaling.  
WO/2013/022345A1
The invention relates to O-acylated O-alkylated monoglycosides, and to their use as plasticizing or coalescing agents for compositions comprising a thermoplastic polymer. The invention further relates to a method for preparing said O-acy...  
WO/2013/022985A3
The present invention relates to compounds involved in nematode signaling.  
WO/2013/020979A1
The present invention relates generally to catechin and epicatechin conjugates of formula (I). For example, a chemical synthesis process for the preparation of catechin and epi-catechin compounds, in particular of catechin and epi-catech...  
WO/2013/019662A1
Provided herein are glycosidic aryl naphthalide lignans compounds, such as justiprocumin A isolated from the plant Justicia gendarussa Burm.f. (Acanthaceae), which are effective in the treatment of AIDS and HIV infections.  
WO/2013/017254A1
The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide a-L-Rhap- ( 1→3 ) -β-D-Glcp- ( 1→4 ) - [a-L-R...  
WO/2013/012737A1
This invention provides new active compounds for pharmaceutical use including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma,...  
WO/2013/008062A1
The present invention relates to a non covalent molecular structure comprising a carbon nanostructure and a pyrene based glycoconjugate (I) which is linked to the said carbon nanostructure by a non covalent link, the said glycoconjugate ...  
WO/2013/004086A1
Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated ...  
WO/2013/003291A3
The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture. Acid t...  
WO/2013/002346A1
Provided are: a (meth) allylsilane compound that is chemically bonded to a variety of alcohol derivatives such as saccharides and other polyol derivatives, is a raw material used to cause a substrate to express functionality such as anti...  
WO/2013/000275A1
Disclosed are compounds as shown as general formula (I), derivatives and uses thereof, wherein R1, R2, R3, R4, R5a, R5b, R5c and X have the definition as same as the description.  
WO/2012/175813A1
This invention relates to synthetic oligo- or multivalent beta- 1 - 2 - linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell -mediated immune responses.  
WO/2012/173477A1
Title: Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable thereby. Abstract The invention relates to drug development and synthetic chemistry, in particul...  
WO/2012/172566A2
The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the pr...  
WO/2012/173942A2
Methods and materials for producing organic syringomycin, the methods include culturing a culture of Pseudomonas syringae and a growth medium including glucose, mannitol, histidine, a magnesium source, an iron source, and a buffer with a...  
WO/2012/173942A3
Methods and materials for producing organic syringomycin, the methods include culturing a culture of Pseudomonas syringae and a growth medium including glucose, mannitol, histidine, a magnesium source, an iron source, and a buffer with a...  
WO/2012/167813A1
The present invention relates to a process, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, until a stationary growth phase is obtained, -cultivating said pre-cultivated cells in ...  
WO/2012/167920A1
The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related inventio...  
WO/2012/168325A1
The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, in absence of a...  
WO/2012/164062A1
The invention relates to triterpenes and triterpene glycosides of the formula (I) and/or physiologically acceptable salts thereof, preferably naturally occurring triterpenes and triterpene glycosides from Mycetia balansae and/or physiolo...  
WO/2012/163508A1
The invention relates to crystalline epirubicin hydrochloride and to a method for producing it. The method for producing crystalline epirubicin hydrochloride comprises the steps of (a) providing epirubicin hydrochloride, (b) preparing a ...  
WO/2012/164074A1
Compounds of the formula (I) (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are, independent of each other, hydrogen or a substituent as described in the specification, and one of RA, RB, RC and RD is P...  
WO/2012/161559A2
The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-densit...  
WO/2012/160337A1
Compounds which interact with HlsTONES Compounds of Formula I : • 4"'-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fucose [alpha]1-3 (4'-Sulfo-Fu- cose [alpha]1-4-Glucuronic acid [beta]1-0-Methyl or • 4" "-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fu...  
WO/2012/161559A3
The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-densit...  
WO/2012/161250A1
Provided is an alpha-glucosidase which is easily obtainable and easily handled, and the enzyme activity of which is activated by an activator, and which effectively does not generate malto-oligosaccharides with a degree of polymerization...  
WO/2012/158965A3
Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based th...  
WO/2012/155916A1
The present invention relates to the synthesis of the tetrasaccharide of formula (I) and novel intermediates used in the synthesis.  
WO/2012/156273A1
A method for the manufacture an infant formula or an infant nutritional product comprising mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2 ...  
WO/2012/146774A1
The present invention concerns a compound of formula (I) the salt, solvate, enantiomer, diastereoisomer and racemic mixture thereof for treating or preventing ischemia/reperfusion injury associated disorders during surgical operations or...  
WO/2012/140596A1
The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ph...  
WO/2012/140596A8
The present invention provides a compound of formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ...  
WO/2012/140576A1
A compound of the formula (I) wherein R1 is a group removable by hydrogenolysis,and wherein R2 is OH or R2 is -NHR3 wherein R3 is a group removable by hydrogenolysis. The compound can be made from fructose by a Heyns-rearrangement. The c...  
WO/2012/142615A3
Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient i...  
WO/2012/141228A1
Provided is a novel therapeutic means for Alzheimer's disease. A compound represented by general formula (I) [wherein Ar1 represents a 2-methoxy-4-(2-pyridylmethoxy)phenyl group or the like; and Ar2 represents a 1H-indole-6-yl group or t...  
WO/2012/142615A2
Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient i...  
WO/2012/139134A3
Described herein, at least in part, are methods of modulating oncogenic fusion proteins.  
WO/2012/132022A1
Provided is a compound represented by the formula (I): wherein R1 represents R5=N- (R5 represents a saccharide residue) or (R4 represents a mono- or polyethylene glycol residue); each of R2 and R3, whether identical or not, represents a ...  
WO/2012/129651A1
The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the com...  
WO/2012/132022A9
Provided is a compound represented by the formula (I): wherein R1 represents R5=N- (R5 represents a saccharide residue) or (R4 represents a mono- or polyethylene glycol residue); each of R2 and R3, whether identical or not, represents a ...  

Matches 351 - 400 out of 12,519